Investigators have functionally linked the Alzheimer’s disease (AD) risk gene SORL1 to apolipoprotein E (ApoE) and clusterin, another apolipoprotein. The work, Tracy Young-Pearse told BioWorld, is part of an attempt to “try to understand different subtypes of Alzheimer’s disease.” It maps some of what Young-Pearse termed the “many molecular roads that lead to Alzheimer’s” – which, in turn, is the first step to setting up roadblocks. Young-Pearse is an associate professor in the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital and Harvard Medical School and co-leader of the Harvard Stem Cell Institute’s Nervous System Diseases Program. She is also the senior author of the paper describing the findings, which appeared online in Cell Reports on Aug. 22, 2023.
A newly discovered antibiotic has been shown to block the synthesis of bacterial cell walls via immutable targets, raising the prospect of a class of drugs that will not lose effect through the development of antimicrobial resistance. Clovibactin, isolated from soil bacteria, targets the cell wall precursor molecules lipid II, lipid III and undecaprenyl phosphate (C55PP), all of which have a pyrophosphate group in common.
Jiangsu Tasly Diyi Pharmaceutical Co. Ltd. has described Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of inflammation, infection, cancer, and autoimmune disease.
Etern Biopharma (Shanghai) Co. Ltd. has divulged transcriptional coactivator YAP1 and TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Sichuan Haisco Pharmaceutical Co. Ltd. has identified phosphodiesterase PDE3 and phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized benzimidazole derivatives acting as serine/threonine-protein kinase SIK2 (QIK) and/or SIK1 (SNF1LK) and/or SIK3 (QSK) inhibitors reported to be useful for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.
Canariabio Inc.'s MAb-AR20.5 has been awarded orphan drug designation by the FDA for pancreatic cancer. MAb-AR20.5 is an IgG1k type murine monoclonal antibody that binds specifically to the circulating and tumor-associated antigen (MUC1) expressed on pancreatic cancer cells.
Influenza A virus (IAV) is an RNA virus that can infect humans and also animals such as birds and pigs with high infectivity. Although there are several groups of anti-IAV drugs in the market, there is a need for new strategies due to the emergence of resistance and the high variability of the virus. One of the potential targets to watch in this disease is hemagglutinin (HA).
RSS
